A causal relationship is not well established. Amiodarone is more effective than sotalol or propafenone in preventing recurrent atrial fibrillation in patients for whom a rhythm-control strategy is chosen. These symptoms often are dosage related and usually improve when the dosage is reduced.Corneal microdeposits are visible on slit-lamp examination in nearly all patients treated with amiodarone.Optic neuropathy and optic neuritis, sometimes progressing to total blindness, have been described in a small number of patients treated with amiodarone. Higgins SL, A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. Roy D, Sanoski CA, These conditions often are dosage related and improve when the dosage is reduced. Hagens VE, et al. Lee DS, Berger Y,
Larger, prospective and interventional studies are recommended. et al. The bioavailability of amiodarone is variable but generally poor, ranging from 22 to 95 percent.The major metabolite of amiodarone is desethylamiodarone (DEA), which is known to have antiarrhythmic properties.
Van Gelder IC, Montvale, N.J.: Medical Economics, 2002.Libersa CC,
Neurological and dermatological evaluations were not recorded for any of the patients, unless symptoms appeared. Substrati delle PgP Harvengt C. All patients were treated for atrial fibrillation or flutter with an oral maintenance dose of 200 mg/d. Rydén LE, New login is not successful because the max limit of logins for this user account has been reached.Login failed. Although the U.S. Food and Drug Administration (FDA) has labeled amiodarone only for the treatment of life-threatening ventricular arrhythmias, the drug also is used to treat atrial fibrillation. This adverse effect occurs at a rate of 0.6 percent annually.Patients with liver toxicity are rarely symptomatic. Cannom DS,
Rosenberg Y, Grant FC, Amiodarone to prevent recurrence of atrial fibrillation. Interventions to improve compliance with these guidelines are needed.Amiodarone, a widely used antiarrhythmic drug, is associated with profound safety concerns.The North American Society for Pacing and Electrophysiology recommends monitoring tests for early detection and mitigation of amiodarone adverse reactions.We conducted a retrospective review of electronic medical records of adult patients treated chronically with amiodarone.
Humbert L, Proactive interventions and increased awareness are needed for improvement. In most instances, the toxicity is reversible.Thyroid toxicity is the most common complication that requires intervention. Frye RL, Rankin et al retrospectively evaluated the monitoring of thyroid and liver functions in Scottish adult patients treated with amiodarone between 1989 and 2011. Evidence from a population-based study in ItalyEnvironmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatmentEffects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation thresholdEffect of chronic amiodarone therapy on defibrillation energy requirements in humansMonitoring the use of amiodarone: compliance with guidelinesThe use and effects of electronic health tools for patient self-monitoring and reporting of outcomes following medication use: systematic reviewSAGE Publications Inc, unless otherwise noted. Multicenter Unsustained Tachycardia Trial Investigators [Published erratum appears in N Engl J Med 2000;342:1300]. Thyroid hormone and the cardiovascular system. After receiving his medical degree from Johns Hopkins University School of Medicine, Baltimore, Dr. Siddoway completed an internal medicine residency and clinical pharmacology and cardiology fellowships at Vanderbilt University Medical Center, Nashville. Any report from the patient of worsening dyspnea or cough should elicit a prompt assessment for pulmonary toxicity.
Russell RO Jr, The source of records was Carmel Medical Center database, part of Clalit Health Services, Israel. The clinical uses of amiodarone, including recommendations for its use in the treatment of various arrhythmias, are discussed separately. AMIODARONE MONITORING PROTOCOL Amiodarone is for initiation by the consultant or specialist only. West Pont, Pa.: Merck & Co., Inc., 2003.Cheitlin MD,
Brique SA, DiMarco JP, Klein I, Improved awareness and repeated structured multisystem evaluation of amiodarone-treated patients may lead to early diagnosis and intervention.Amiodarone can cause by itself cardiac arrhythmias and blocks.The significant gaps in the adherence to amiodarone monitoring guidelines are probably the consequences of several factors. However, the drug has many other effects: it slows heart rate and atrioventricular nodal conduction (via calcium channel and beta-receptor blockade), prolongs refractoriness (via potassium and sodium channel blockade), and slows intracardiac conduction (via sodium channel blockade).The relationship between plasma amiodarone concentrations and effect, as well as the contribution of the metabolite DEA, is not well established.Amiodarone is approved for use in the secondary prevention of life-threatening ventricular arrhythmias. Prystowsky EN,
Recognition and pathogenesis (part I)Serial lung function testing in patients treated with amiodarone: a prospective studyAdverse effects of low dose amiodarone: a meta-analysisComplex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid glandAmiodarone-associated proarrhythmic effects.
Epstein AE, All rights Reserved.
Dorian P, Data were transferred to an electronic data sheet (Microsoft Excel 365) and subjected to descriptive analysis.